Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
Clicks: 3
ID: 296986
1998
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
0.6
/100
3 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #67 of 310 articles by views in european heart journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 310 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Patients with CHDor other atherosclerotic disease.Screen close relatives of patients with premature (men <55 yrs, women <65 yrs) CHD. LifestyleStop smoking, make healthy food choices, be physically active and achieve ideal weight. Other risk factorsBlood pressure <140/90 mmHg, Total cholesterol <5.0 mmol/l (190 mg/dl) LDL-cholesterol <3.0 mmol/l (115 mg/dl) When these risk factor goals are not achieved by lifestyle changes, blood pressure and cholesterol lowering drug therapies should be used.Healthy high risk individuals.Absolute CHD risk ≥20% over 10 years, or will exceed 20% if projected to age 60.Aspirin (at least 75mg) for all coronary patients, those with cerebral atherosclerosis and peripheral atherosclerotic disease.ß-blockers in patients following myocardial infarction.ACE inhibitors in those with symptoms or signs of heart failure at the time of myocardial infarction, or with chronic LV systolic dysfunction (ejection fraction <40%).Anticoagulants in selected coronary patients.Screen close relatives if familial hypercholesterolaemia or other inherited dyslipidaemia is suspected.Aspirin (75 mg) in treated hypertensive patients and in men at particularly high CHD risk. Lifestyle and therapeutic goals for patients with CHD, or other atherosclerotic disease, and for healthy high risk individualsOther prophylactic drug therapies Screen close relatives Table 1 1436 Task Force Report
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (14 words).
Try re-searching for a better abstract.
| Reference Key |
openalex_W2517252201
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Second Joint Task Force of European |
| Journal | european heart journal |
| Year | 1998 |
| DOI |
10.1053/euhj.1998.1243
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.